Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094955 | 0.84 | CYP1A2 (0.44) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL318609 | 0.83 | CES2 (0.45) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL29975434 | 0.83 | CES2 (0.45) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL28509492 | 0.81 | SELL (0.48) | CYP1A2ALBKDM4ETSHRCASP1 | |
| SCHEMBL2827111 | 0.81 | CES2 (0.48) | CES2CES1BCHEDGAT1SMN1; SMN2 | |
| SCHEMBL25313813 | 0.81 | DGAT1 (0.55) | CES2CES1MAP2K1MAP2K2BCHE | |
| SCHEMBL16122327 | 0.81 | CYP1A2 (0.41) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL29741520 | 0.81 | CES2 (0.48) | CES2CES1BCHEDGAT1SMN1; SMN2 | |
| SCHEMBL241797 | 0.79 | CES2 (0.70) | CES2CES1CYP1A2MAP2K1MAP2K2 | |
| SCHEMBL7555550 | 0.79 | TSHR (0.44) | CES2CES1CYP1A2MAP2K1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112138427-B | Preparation method of polysubstituted fluorine-containing bromophenol benzoic acid | 上海罕道医药科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-112138427-A | Preparation method of polysubstituted fluorine-containing bromophenol benzoic acid | 上海罕道医药科技有限公司 | 2020-12-29 | — | — | CN | claimed |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| EP-4584258-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014037480-A1 | 6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-13 | — | — | WO | disclosed |
| EP-0734380-B1 | 4-BENZOYLISOXAZOLES AND THEIR USE AS HERBICIDES | AVENTIS AGRICULTURE LTD (GB) | 2002-07-10 | — | — | EP | disclosed |
| US-6369270-B1 | CHEMICAL INTERMEDIATES | RHONE POULENC AGRICULTURE LIMITED (GB) | 2002-04-09 | — | — | US | disclosed |
| US-6114538-A | 2-POSITION OF BENZOY RING OF 4-BENZOYLISOXAZOLE DERIVATIVE IS SUBSTITUTED AND PARTICULARLY USED AGAINST MONOCOTYLEDONOUS WEEDS BY POST-EMEREGENECE APPLICATION | RHONE POULENC AGRICULTURE LIMITED (GB) | 2000-09-05 | — | — | US | disclosed |
| US-5998653-A | CHEMICAL INTERMEDIATE FOR HERBICIDES | RHONE POULENC AGRICULTURE LIMITED (GB) | 1999-12-07 | — | — | US | disclosed |
| US-5658858-A | POSTEMERGENCE HERBICIDES | RHONE-POULENC ARGRICULTURE LIMITED (GB) | 1997-08-19 | — | — | US | disclosed |
| EP-0734380-A1 | 4-BENZOYLISOXAZOLES AND THEIR USE AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016678-A1 | 4-BENZOYLISOXAZOLES AND THEIR USE AS HERBICIDES | RHONE POULENC AGRICULTURE LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | CES2 4366/4885CES1 2465/4885CYP1A2 4381/4885 |
| US-12156916-B2 | Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use | BRAF, ARAF, RAF1 | CES2 3454/4885CES1 2284/4885CYP1A2 2531/4885 |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | CES2 3160/4885CES1 1023/4885CYP1A2 4455/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | CES2 565/4885CES1 622/4885CYP1A2 3302/4885 |
| US-20250161465-A1 | RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARAF, BRAF, HRAS | CES2 2235/4885CES1 1537/4885CYP1A2 2585/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | CES2 3172/4885CES1 1326/4885CYP1A2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.